

## ***VCN Biosciences Announces Publication in Peer-Reviewed Journal of Controlled Release of Preclinical Research on an Oncolytic Adenovirus with Hyaluronidase Activity that Evades Neutralizing Antibodies***

---

Barcelona, March 24, 2021.- VCN Biosciences, a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses, today announced the publication of preclinical research on promising therapy VCN-11 in Peer-Reviewed Journal of Controlled Release.

Highlights from the article include:

- VCN-11 is a new oncolytic adenovirus that expresses hyaluronidase and displays an albumin-binding domain on its capsid.
- VCN-11 has shown a good efficacy and safety profile in different animal models.
- Hyaluronidase expression allows VCN-11 to disrupt the tumor extracellular matrix favoring viral dissemination.
- An Albumin Shield (ABS) protects VCN-11 from antibody neutralization and enables effective readministration.
- VCN-11 is a promising therapy to be tested under repeated administrations in cancer patients

Miriam Bazan-Peregrino, DPhil, VCN Biosciences R&D Director, said, “It is very rewarding to see our manuscript on our new preclinical platform VCN-11 be published in the peer-reviewed Journal of Controlled Release. The fact that VCN-11 can evade neutralizing antibodies and be readministered effectively, makes it a real therapeutic option. We want to thank and congratulate all scientist involved in this exciting project for their contribution.”

The publication is now available electronically at:

<https://authors.elsevier.com/a/1cliLcl2%7EwTwF>

### ***About VCN Biosciences***

VCN Biosciences is a clinical-stage immuno-oncology company focused on the development of the next generation of oncolytic adenoviruses. VCN candidates are designed to obtain clinical activity after systemic administration and are able to remodel the complex matrix in the tumor to allow enhanced spreading of therapeutic molecules and the immune system. VCN Biosciences lead product, VCN-01, is a oncolytic adenovirus with unique characteristics being studied in clinical trials for cancers for which there is no cure, including pancreatic carcinoma and retinoblastoma. For more information, please visit [www.vcnbiosciences.com](http://www.vcnbiosciences.com).